Potential MS drug RPC1063 meets primary objective ....
Posted: Mon Jun 10, 2013 2:37 am
Potential MS drug RPC1063 meets primary objective in TQT study
Receptos, Inc. said its oral, once daily, selective and potent S1P1R modulator RPC1063 completed a thorough QT/QTc or TQT study of herart's electrical conduction system and met its primary objective. The company also obtained special protocol assessments or SPA from FDA for Phase 3 Trials in Relapsing Multiple Sclerosis.
RPC1063 is currently in development for autoimmune indications and being studied in randomized Phase 2 trials for the treatment of relapsing multiple sclerosis and ulcerative colitis.... Read More - http://www.ms-uk.org/index.cfm/RPC1063
Receptos, Inc. said its oral, once daily, selective and potent S1P1R modulator RPC1063 completed a thorough QT/QTc or TQT study of herart's electrical conduction system and met its primary objective. The company also obtained special protocol assessments or SPA from FDA for Phase 3 Trials in Relapsing Multiple Sclerosis.
RPC1063 is currently in development for autoimmune indications and being studied in randomized Phase 2 trials for the treatment of relapsing multiple sclerosis and ulcerative colitis.... Read More - http://www.ms-uk.org/index.cfm/RPC1063